Cancer Family
Lymphocytic Neoplasm
CI-CAN-00000223Explore in graph →
HematologicNon-malignant3,036 active trials72 approved drugs345 evidence items
- NCIt
- C7065
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000223Explore in graph →
Clinical trials
12,949 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01237054 | Imaging in MGUS, SMM and MM | completed | Phase 2 | 31 | National Cancer Institute (NCI)NIH | 1 | Feb 6, 2026 | clinicaltrials |
| NCT04849416 | A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia) | completed | Phase 2 | 87 | Eli Lilly and CompanyINDUSTRY | 1 | Feb 6, 2026 | clinicaltrials |
| NCT01745640 |
| Pomalidomide and Dexamethasone Effects in Multiple Myeloma Patients With Del 17p or t (4;14)(IFM2010-02) |
| completed |
| Phase 2 |
| 63 |
| University Hospital, LilleOTHER |
| 1 |
| Feb 5, 2026 |
| clinicaltrials |
| NCT02315326 | Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL) | completed | Phase 1 / Phase 2 | 93 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 2, 2026 | clinicaltrials |
| NCT00875056 | Study of Vorinostat (MK-0683) With Follicular Lymphoma (FL), Other Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL), or Mantle Cell Lymphoma (MCL) Participants (MK-0683-103) | completed | Phase 2 | 56 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jan 30, 2026 | clinicaltrials |
| NCT03204188 | Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | completed | Phase 2 | 15 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Jan 30, 2026 | clinicaltrials |
| NCT04116437 | Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment | completed | Phase 2 | 96 | BeiGeneINDUSTRY | 1 | Jan 28, 2026 | clinicaltrials |
| NCT03159702 | Propylene Glycol-Free Melphalan HCl (EVOMELA®) in Combination With Fludarabine and Total Body Irradiation Based Reduced Intensity Conditioning for Haploidentical Transplantation | completed | Phase 2 | 43 | Medical College of WisconsinOTHER | 1 | Jan 27, 2026 | clinicaltrials |
| NCT03740529 | A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL | completed | Phase 1 / Phase 2 | 803 | Loxo Oncology, Inc.INDUSTRY | 10 | Jan 27, 2026 | clinicaltrials |
| NCT04401774 | Nivolumab Maintenance in Newly Diagnosed PCNSL With Persistent CSF Circulating Tumor DNA After Completion of First-Line Chemotherapy | completed | Phase 2 | 14 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 27, 2026 | clinicaltrials |
| NCT02389517 | Lenalidomide With or Without Ixazomib Citrate and Dexamethasone in Treating Patients With Residual Multiple Myeloma After Donor Stem Cell Transplant | completed | Phase 2 | 42 | University of ChicagoOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT00364286 | Therapy of Chronic Lymphocytic Leukemia With Dasatinib (BMS-354825) | completed | Phase 2 | 17 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT02969837 | Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma | completed | Phase 2 | 46 | University of ChicagoOTHER | 1 | Jan 16, 2026 | clinicaltrials |
| NCT05466994 | A Phase II Randomized Controlled Trial to Determine the Efficacy of an auGmented reAlity gaMe in pediatrIc caNcer Patients Who Are Opioid Naïve Undergoing Surgery to Reduce Postoperative Opioid Use (GAMING-ON Study) | completed | Phase 2 | 29 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 15, 2026 | clinicaltrials |
| NCT02896582 | Efficacy of Upfront and Maintenance Obinutuzumab in Mantle Cell Lymphoma Treated by DHAP and MRD Driven Maintenance(LyMa101) | completed | Phase 2 | 86 | The Lymphoma Academic Research OrganisationOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT02264613 | ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas | completed | Phase 1 / Phase 2 | 142 | Aileron Therapeutics, Inc.INDUSTRY | 1 | Jan 13, 2026 | clinicaltrials |
| NCT02441686 | Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma | completed | Phase 2 | 46 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 13, 2026 | clinicaltrials |
| NCT03210662 | Pembrolizumab and External Beam Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma | completed | Phase 2 | 17 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 13, 2026 | clinicaltrials |
| NCT06558513 | To Evaluate a Phase I/II Clinical Study of XNW5004 Tablets in Patients With Relapsed/Refractory Advanced Tumors | completed | Phase 1 / Phase 2 | 120 | Evopoint Biosciences Inc.INDUSTRY | 1 | Jan 12, 2026 | clinicaltrials |
| NCT02490891 | Study of the Angiogenesis by PET/CT in Patients With Lymphoma(RGDLymphome) | completed | Phase 2 | 21 | Centre Henri BecquerelOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT06322342 | Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent | completed | Phase 2 | 18 | Reveal Pharmaceuticals Inc.INDUSTRY | 1 | Dec 26, 2025 | clinicaltrials |
| NCT06511895 | AZD4205 in Relapsed or Refractory Peripheral T Cell Lymphoma (JACKPOT27) | completed | Phase 2 | 57 | Dizal PharmaceuticalsINDUSTRY | 1 | Dec 24, 2025 | clinicaltrials |
| NCT03105336 | A Study of Axicabtagene Ciloleucel in Participants With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma(ZUMA-5) | completed | Phase 2 | 159 | Kite, A Gilead CompanyINDUSTRY | 2 | Dec 23, 2025 | clinicaltrials |
| NCT01665794 | Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 25 | University of ChicagoOTHER | 2 | Dec 22, 2025 | clinicaltrials |
| NCT05120570 | PTCy + Sirolimus/VIC-1911 as GVHD Prophylaxis in Myeloablative PBSC Transplantation | completed | Phase 1 / Phase 2 | 16 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 22, 2025 | clinicaltrials |
| NCT00466674 | Treatment of Myeloma in Patients <= 65 Years Old With Response >= 50% After HSC Autotransplant by Allogenic Transplant Genoidentical or Phenoidentical After Reduced Intensity Conditioning(IFM 2005-03) | completed | Phase 2 | 13 | Hospices Civils de LyonOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT01496976 | Ofatumumab, High Dose Methylprednisolone, Ofatumumab and Lenalidomide Consolidative Therapy for Untreated CLL/SLL | completed | Phase 2 | 45 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT02461888 | Phase II Randomised Trial of Cyclophosphamide & Dexamethasone in Combination With Ixazomib in Relapsed or Refractory Multiple Myeloma.(MUKEight) | completed | Phase 2 | 112 | University of LeedsOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT03317899 | Stem Cell Transplant With or Without Tbo-filgrastim in Treating Patients With Multiple Myeloma or Non-Hodgkin Lymphoma | completed | Phase 2 | 77 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT02005289 | Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL | completed | Phase 2 | 41 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT04191187 | Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies | completed | Phase 2 | 34 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT02328014 | Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies | completed | Phase 1 / Phase 2 | 40 | Acerta Pharma BVINDUSTRY | 1 | Dec 9, 2025 | clinicaltrials |
| NCT03567876 | Rituximab, Bendamustine and Cytarabine Followed by Venetoclax in High Risk Elderly Patients With MCL | completed | Phase 2 | 141 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Dec 8, 2025 | clinicaltrials |
| NCT05991973 | Low-dose Chidamide Maintenance Therapy After Allo-HSCT for T-cell Acute Lymphoblastic Leukemia or T-cell Lymphomas | completed | Phase 2 | 44 | Zhejiang UniversityOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT02302469 | Study of Lenalidomide in Relapse/Refractory Waldenstrom Macroglobulinemia(RV-WM-0426) | completed | Phase 1 / Phase 2 | 17 | University Hospital, LilleOTHER | 1 | Nov 28, 2025 | clinicaltrials |
| NCT04150913 | A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity | completed | Phase 2 | 15 | Marcela V. Maus, M.D.,Ph.D.OTHER | 1 | Nov 25, 2025 | clinicaltrials |
| NCT01286272 | Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma | completed | Phase 2 | 135 | National Cancer Institute (NCI)NIH | 1 | Nov 24, 2025 | clinicaltrials |
| NCT02588651 | A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL) | completed | Phase 2 | 23 | Deepa JagadeeshOTHER | 1 | Nov 21, 2025 | clinicaltrials |
| NCT02937571 | High Dose Carfilzomib for Newly Diagnosed Myeloma | completed | Phase 1 / Phase 2 | 29 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT04214626 | R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma | completed | Phase 2 | 60 | Henan Cancer HospitalOTHER_GOV | 1 | Nov 19, 2025 | clinicaltrials |
| NCT03160079 | Blinatumomab & Pembrolizumab for Adults With Relapsed/Refractory B-cell ALL With High Marrow Lymphoblasts | completed | Phase 1 / Phase 2 | 16 | University of California, San DiegoOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT02875548 | A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated With Tazemetostat in a Previous Clinical Study(TRuST) | completed | Phase 1 / Phase 2 | 58 | Epizyme, Inc.INDUSTRY | 7 | Nov 4, 2025 | clinicaltrials |
| NCT01760655 | Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies | completed | Phase 2 | 62 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Oct 30, 2025 | clinicaltrials |
| NCT04875195 | A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68) | completed | Phase 2 | 66 | Merck Sharp & Dohme LLCINDUSTRY | 11 | Oct 29, 2025 | clinicaltrials |
| NCT00310037 | Bortezomib After Combination Chemotherapy, Rituximab, and an Autologous Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma | completed | Phase 2 | 151 | Alliance for Clinical Trials in OncologyOTHER | 1 | Oct 28, 2025 | clinicaltrials |
| NCT04359784 | Anakinra for the Prevention of Cytokine Release Syndrome and Neurotoxicity in Patients With B-Cell Non-Hodgkin Lymphoma Receiving CD19-Targeted CAR-T Cell Therapy | completed | Phase 2 | 27 | Fred Hutchinson Cancer CenterOTHER | 1 | Oct 23, 2025 | clinicaltrials |
| NCT01592370 | An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma | completed | Phase 1 / Phase 2 | 320 | Bristol-Myers SquibbINDUSTRY | 6 | Oct 22, 2025 | clinicaltrials |
| NCT01508312 | Brentuximab Vedotin (SGN-35) in Transplant Eligible Patients With Relapsed or Refractory Hodgkin Lymphoma | completed | Phase 2 | 66 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 21, 2025 | clinicaltrials |
| NCT03767257 | A Study of Colesevelam for Lenalidomide-Associated Diarrhea | completed | Phase 2 | 25 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 21, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Feb 6, 2026source: clinicaltrials